Insulin icodec + semaglutide

Insulin icodec + semaglutide has been studied in 4 papers since 2026: 2 trials in people, 2 reviews; 4 in the past year. The newest story, Nov 1, 2026: “IcoSema analysis suggests no effect on hospitalization”.

Intervention

4 papers study it7 findingsUpdated

2 new papers in 30 daysSee all 4 papers on insulin icodec + semaglutide

At a glance

Insulin icodec plus semaglutide lowers LDL cholesterol, systolic blood pressure and body weight in a human trial, with no clear HbA1c effect. Another trial in type 2 diabetes shows no clear effect on hospitalization incidence or duration versus active comparators. One group reports the human results; Novo Nordisk appears as a funder and author affiliation.

7 findings in 3 papers since June 2026

The findings reach people, from one lab or study. 3 independent labs in 1 country.

“Post hoc findings suggest that IcoSema did not affect hospitalisation incidence or duration”
Insights on hospitalisations from the phase 3a COMBINE 1–3 trials of once-weekly IcoSema in individuals with type 2 diabetes: a post hoc analysisMetabologia2026doi:10.1007/s44357-026-00025-3

None of its findings points the other way.

Humans: a single group. Cells, worms or flies and mice: nothing yet.
  • 3 independent labs in 1 country
  • Funder: Novo Nordisk
  • 1 of 7 findings with company ties
  • Human trial2

Studies in people

1 study gave insulin icodec + semaglutide to people and measured what changed.

What changedDesignPeopleSource

up: Increases time in range54.8% to 78.1%; 95% CI 9.5–25.5

no change: Has no effect on gastrointestinal adverse eventsnone observed

Trial66 peopleBothmean 61.8 ± 9.0 yearsDual therapy after switching from three or more glucose-lowering agents, compared with original therapyADA Scientific Sessions 2026 abstract, Jun 5, 2026

What did studies of insulin icodec + semaglutide find?

7

Studies of insulin icodec + semaglutide measured 7 outcomes, among them hospitalization incidence and duration, LDL cholesterol and HbA1c.

Hospitalization incidence and duration

no changein humans1

1 study
  1. Insulin icodec + semaglutide showed no clear effect on hospitalization incidence and duration in humans (type 2 diabetes; compared with active comparators) (Hospitalized: 106/1325 versus 92/1312; median stay: 4.0 versus 5.0 days).

    Human trialtype 2 diabetes; compared with active comparatorsonce-weeklyn = 2,637

    IcoSema analysis suggests no effect on hospitalization

    Metabologia

LDL cholesterol

downin humans1

1 study
  1. Insulin icodec + semaglutide decreases LDL cholesterol in humans (ETR 0.94, 95% CI 0.90–0.98).

    Human trialn = 1,970

More on LDL cholesterol

HbA1c

no changein humans1

1 study
  1. Insulin icodec + semaglutide showed no clear effect on HbA1c in humans (MD -0.37%, 95% CI -0.95 to 0.21).

    Human trialn = 1,970

More on HbA1c

Systolic blood pressure

downin humans1

1 study
  1. Insulin icodec + semaglutide decreases systolic blood pressure in humans (MD -2.45 mmHg, 95% CI -3.52 to -1.38).

    Human trialn = 1,970

Body weight

downin humans1

1 study
  1. Insulin icodec + semaglutide decreases body weight in humans (MD -6.10 kg, 95% CI -7.21 to -5.00).

    Human trialn = 1,970

Gastrointestinal adverse events

no changein humans1

1 study
  1. Insulin icodec + semaglutide was not clearly linked with gastrointestinal adverse events in humans (dual therapy) (none observed).

    Humansdual therapyn = 66

Time in range

upin humans1

1 study
  1. Insulin icodec + semaglutide is linked with higher time in range in humans (54.8% to 78.1%; 95% CI 9.5–25.5).

    Humansdual therapy after switching from three or more glucose-lowering agents, compared with original therapyn = 66

More on Time in range

How this record changed

  1. Summary rewritten as its findings changed.

    As it read before

    Human trials report weight loss with insulin icodec plus semaglutide in type 2 diabetes, independently replicated across labs; systolic blood pressure and LDL cholesterol also decrease in patients inadequately controlled on basal insulin. HbA1c results differ between reduction and no effect. Two of six findings name Novo Nordisk as funder and have Novo Nordisk-affiliated authors.

  2. Summary written from the findings.

Latest

Dec 2025: 0Jan 2026: 0Feb 2026: 1Mar 2026: 0Apr 2026: 0May 2026: 0Jun 2026: 1Jul 2026: 0Aug 2026: 0Sep 2026: 1Oct 2026: 1Nov 2026: 04 papers in 12 months
Metabologia

IcoSema analysis suggests no effect on hospitalization

Hospitalization occurred in 106 of 1,325 IcoSema recipients and 92 of 1,312 comparator recipients; median stays were 4.0 and 5.0 days, respectively.Hospitalization occurred in 106 of 1,325 IcoSema recipients and 92 of 1,312 comparator recipients; median stays were 4.0 and 5.0 days, respectively.

Randomized trial · 2,637 peopleInterventions